Table 1.
Clinical parameters
| Clinical parameter | Crohn’s disease | Healthy donors |
|---|---|---|
| n = 17 | n = 7 | |
| Male [%] | 14 [82.35] | 4 [57.1] |
| Age at enrolment [mean ± SD, yr] | 41.9 [±11.8] | 64.9 [±8.1] |
| Disease duration [mean ± SD, yr] | 15.4 [±10] | - |
| Smoking status [yes/no/ex] | 5/2/10 | - |
| Crohn’s disease location [] | ||
| L1 [ileal] | 2 [11.76] | - |
| L2 [colonic] | 1 [5.88] | - |
| L3 [ileocolonic] | 14 [82.35] | - |
| L4 [upper disease] | 0 [0] | - |
| Crohn’s disease behaviour [%] | ||
| B1 [non-stricturing, non-penetrating] | 3 [17.64] | - |
| B2 [stricturing] | 2 [11.76] | - |
| B3 [penetrating] | 12 [70.58] | - |
| Concomitant therapy at enrolment [%] | 3 [17.64] | - |
| Antibiotics [%] | ||
| Mesalazine [%] | 2 [11.76] | - |
| Thiopurines[%] | 3 [17.64] | - |
| Corticosteroids [%] | 2 [11.76] | - |
| Anti-TNF | 6 [35.29] | - |
| Vedolizumab | 1 [5.88] | - |
| Anti-IL23 | 1 [5.88] | - |
| None | 4 [23.52] | - |
| HBI score [median; IQR] | 6 [3.5] | - |
| SES-CD [median; IQR] | 8.5 [4.25] | - |
SD, standard deviation; yr, year; TNF, tumour necrosis factor; HBI, Harvey-Bradshaw Index; SES-CD, Simple endoscopic score for Crohn’s disease.